Trial
NCT04904549
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi Pasteur, a Sanofi Company
Collaborators
—
Condition
COVID-19
Intervention
SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series)
Why stopped
The study was terminated as per Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-03